Clinical trial

Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease

NCT07348250

Study summary

ClinicalTrials.gov

Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease

Design: INTERVENTIONAL · Status: TERMINATED · Phase: EARLY_PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention [18F]MK-0947 Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2025-12-08

PhaseEARLY_PHASE1

Conditions

Parkinson's Disease (PD)unresolved

Parkinson's Diseaseverified · MONDO: Parkinson disease

Parkinson's Disease (Disorder)unresolved

Interventions

[18F]MK-0947DRUG

Sponsors & collaborators

Invicrolead sponsor

Merck Sharp & Dohme LLCcollaborator

Mapped research locations

New HavenConnecticut, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07348250 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.